3.10
0.42 (15.63%)
| Previous Close | 2.68 |
| Open | 2.66 |
| Volume | 42,276 |
| Avg. Volume (3M) | 12,562 |
| Market Cap | 26,476,008 |
| Price / Earnings (TTM) | 0.279 |
| Price / Sales | 1.19 |
| Price / Book | 5.26 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -2.07 |
| Total Debt/Equity (MRQ) | 134.23% |
| Current Ratio (MRQ) | 0.220 |
| Operating Cash Flow (TTM) | -4.12 M |
| Levered Free Cash Flow (TTM) | -2.59 M |
| Return on Assets (TTM) | -7.06% |
| Return on Equity (TTM) | -147.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Impact BioMedical, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | -5.0 |
| AI Insight | NA |
| Weighted Average | -1.00 |
Select this tab to load the latest available analysis.
|
Impact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. It provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. The company also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, it develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. The company was incorporated in 2018 and is based in Houston, Texas. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 39.26% |
| % Held by Institutions | 3.19% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Global Trust Asset Management, Llc | 30 Jun 2026 | 144 |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |